J&J re­leas­es PhI­II safe­ty blue­print for Covid-19 vac­cine tri­al. How does it stack up to Mod­er­na, Pfiz­er and As­traZeneca?

Along with the ini­ti­a­tion of its Phase III Covid-19 vac­cine study an­nounced Wednes­day morn­ing, John­son & John­son al­so re­leased its tri­al pro­to­col, giv­ing an in­side look at how the com­pa­ny is con­duct­ing its late-stage re­search.

The move comes af­ter the oth­er three com­pa­nies con­duct­ing Phase III’s in the US — Mod­er­na, Pfiz­er and As­traZeneca — each dis­closed their own tri­al blue­prints with­in the last week. Though the re­lease of such pro­to­cols is typ­i­cal­ly done af­ter tri­als have been com­plet­ed, drug de­vel­op­ers had come un­der in­tense pres­sure af­ter a brief safe­ty scare in an As­traZeneca tri­al and amid grow­ing con­cern of a po­lit­i­cal­ly mo­ti­vat­ed vac­cine au­tho­riza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER